This follows the resignation of Narelle Warren from the joint company secretary role effective on April 7, 2021.
The MGC Pharma board expresses its appreciation to Mrs Warren for her contribution to the company during her tenure which included the successful dual listing on the London Stock Exchange in February.
Corporate secretary experience
New joint company secretary Nadine Barry has three years of experience working as a corporate secretary for Chieftain Securities Pty Ltd, a boutique corporate advisory, equity capital markets and venture capital firm.
In this role, she has been working with small to mid-cap listed companies in the biopharma, resources and energy sectors.
Chief financial officer Daniel Kendall will also assist Ms Barry in the joint company secretary role.
Equity incentive changes
Following the recent dual LSE listing and in conjunction with key advisors in the United Kingdom, the company has agreed to market appropriate changes to the remuneration and equity incentive structures of the executive directors and key management personnel.
This includes a new performance rights program structured to retain the services of key personnel managing the company’s business and to bring in line with similar listed companies in the biopharma sector in the United Kingdom.
MGC Pharma is a European-based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.
The company has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.
Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the company’s EUGMP Certified manufacturing facility.